A pivotal decade for bispecific antibodies?
Sign Up to like & getrecommendations! Published in 2024 at "mAbs"
DOI: 10.1080/19420862.2024.2321635
Abstract: ABSTRACT Bispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of mAbs and their adoption as therapeutic agents in the… read more here.
Keywords: oncology; bsabs; decade bispecific; pivotal decade ... See more keywords
Ensuring equitable access to bispecific antibodies in multiple myeloma: Findings from the emmbrace patient and public involvement and engagement (PPIE) sessions.
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-6186
Abstract: Background: Bispecific antibodies (BsAbs) are effective treatments for relapsed/refractory multiple myeloma (RRMM), but uptake remains inequitable. Outpatient step-up dosing protocols have increased access in community hospitals, but barriers such as patient awareness, understanding and acceptance… read more here.
Keywords: bsabs; equitable access; care; access ... See more keywords
Comparison of infectious complications in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells vs bispecific antibodies
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-782
Abstract: INTRODUCTION: T-cell redirecting strategies (TRS), including chimeric antigen receptor (CAR) T cells and bispecific antibodies (BsAbs), have significantly improved the prognosis of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). However, they are associated with… read more here.
Keywords: bsabs; cohort; car; cell ... See more keywords